JP2024518426A5 - - Google Patents
Info
- Publication number
- JP2024518426A5 JP2024518426A5 JP2023568475A JP2023568475A JP2024518426A5 JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5 JP 2023568475 A JP2023568475 A JP 2023568475A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5
- Authority
- JP
- Japan
- Prior art keywords
- aciminib
- pharmaceutically acceptable
- acceptable salt
- combination
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187023P | 2021-05-11 | 2021-05-11 | |
| US63/187,023 | 2021-05-11 | ||
| PCT/IB2022/054321 WO2022238884A1 (en) | 2021-05-11 | 2022-05-10 | Dosing regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518426A JP2024518426A (ja) | 2024-05-01 |
| JP2024518426A5 true JP2024518426A5 (cg-RX-API-DMAC7.html) | 2025-05-01 |
Family
ID=81846537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568475A Pending JP2024518426A (ja) | 2021-05-11 | 2022-05-10 | 投与レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240245666A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4337205A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024518426A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240006600A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117396202A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218550A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308095A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022238884A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120239604A (zh) * | 2023-11-01 | 2025-07-01 | 深圳市塔吉瑞生物医药有限公司 | 治疗白血病的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2670601T3 (es) * | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1 |
| CN112110880B (zh) * | 2020-09-29 | 2022-09-09 | 天津红日药业股份有限公司 | 雄甾烷衍生物及其制备方法与应用 |
-
2022
- 2022-05-10 WO PCT/IB2022/054321 patent/WO2022238884A1/en not_active Ceased
- 2022-05-10 CN CN202280034821.XA patent/CN117396202A/zh active Pending
- 2022-05-10 JP JP2023568475A patent/JP2024518426A/ja active Pending
- 2022-05-10 US US18/559,859 patent/US20240245666A1/en active Pending
- 2022-05-10 IL IL308095A patent/IL308095A/en unknown
- 2022-05-10 KR KR1020237041919A patent/KR20240006600A/ko active Pending
- 2022-05-10 CA CA3218550A patent/CA3218550A1/en active Pending
- 2022-05-10 EP EP22725540.3A patent/EP4337205A1/en active Pending